emtricitabine

also known as FTC · emtricitabina · Emtriva · 524-W-91 · BW-524W91 · Coviracil · emtricitabine (FTC) · Emtricitabine component of atripla · +11 more

Other / unclassified

Developed for: HIV infectious disease · chronic hepatitis B virus infection · AIDS · COVID-19 · hepatitis B virus infection · cognitive disorder · Alzheimer disease · immunodeficiency disease
+14 more
· Aicardi-Goutieres syndrome · disease related to solid organ transplantation · HIV wasting syndrome · hyperlipidemia · long COVID-19 · lymphoma · metabolic dysfunction-associated steatotic liver disease · multiple sclerosis · primary biliary cholangitis · primary viral infectious disease · psoriasis · cognitive impairment with or without cerebellar ataxia · coronary atherosclerosis · early-onset autosomal dominant Alzheimer disease
Investigated by: Gilead Sciences · National Institute of Allergy and Infectious Diseases (NIAID) · Merck Sharp & Dohme LLC · ANRS, Emerging Infectious Diseases · National Institute of Mental Health (NIMH) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
+256 more
· ViiV Healthcare · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · University of North Carolina, Chapel Hill · Emory University · Johns Hopkins University · Kirby Institute · Triangle Pharmaceuticals · University of Washington · Asian-Pacific Alliance of Liver Disease, Beijing · Beijing Ditan Hospital · Bill and Melinda Gates Foundation · Bristol-Myers Squibb · HIV Prevention Trials Network · Hebei Medical University Pharmaceutical Factory · National Health and Family Planning Commission, P.R.China · University of California, Los Angeles · Abbott · California HIV/AIDS Research Program · French National Agency for Research on AIDS and Viral Hepatitis · Imperial College London · National Institute on Drug Abuse (NIDA) · St Stephens Aids Trust · University of California, San Francisco · Centers for Disease Control and Prevention · Fenway Community Health · Fundacion Clinic per a la Recerca Biomédica · Janssen Pharmaceutica · MRC/UVRI and LSHTM Uganda Research Unit · National Institutes of Health (NIH) · Oswaldo Cruz Foundation · Pfizer · Radboud University Medical Center · University of California, San Diego · AIDS Project Los Angeles · Africa Health Research Institute · Andrew Carr · Assistance Publique - Hôpitaux de Paris · Brigham and Women's Hospital · CONRAD · Catholic University of the Sacred Heart · Chelsea and Westminster NHS Foundation Trust · Dupont Applied Biosciences · Friends Research Institute, Inc. · Fundacion SEIMC-GESIDA · Hoffmann-La Roche · Impact Research & Development Organization · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · International AIDS Vaccine Initiative · International Antiviral Therapy Evaluation Center · Janssen Research & Development, LLC · Janssen Sciences Ireland UC · Janssen Scientific Affairs, LLC · Kenneth H. Mayer, MD · Kenya Medical Research Institute · Kenya National AIDS & STI Control Programme · King's College London · Los Angeles County Department of Public Health · Mexican Social Security Institute · Oak Crest Institute of Science · PENTA Foundation · Public Health Foundation Enterprises, Inc. · San Francisco Department of Public Health · The Miriam Hospital · The University of Texas Health Science Center, Houston · The University of Texas Medical Branch, Galveston · UNITAID · United States Agency for International Development (USAID) · University College, London · University of Cincinnati · University of Colorado, Denver · University of Maryland, Baltimore · University of Nairobi · University of Zimbabwe · Weill Medical College of Cornell University · all 262 on the full record

Regulatory milestones approvals, filings & regulatory actions · 10 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed HIV infectious disease 6 milestones
Filed	EU (EMA)	—	HIV infectious disease	2017-07-13	“Marketing Authorization Application for BIC/FTC/TAF has been fully validated and is now under evaluation by the European Medicines Agency” gilead.com ↗
Filed	EU (EMA)	—	HIV infectious disease	2015-08-20	“Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and...” gilead.com ↗
Filed	EU (EMA)	—	HIV infectious disease	2015-05-28	“MAA for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) has been fully validated” gilead.com ↗
Filed	US (FDA)	Emtriva	HIV infectious disease	2015-04-07	“submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for two doses of an investigational fixed-dose combination of emtricitabine” gilead.com ↗ “Emtricitabine for the treatment of HIV were submitted to U.S. and European regulatory authorities in September and December of 2002, respectively” gilead.com ↗
Filed	EU (EMA)	—	HIV infectious disease	2014-12-23	“elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) was fully validated on December 23, 2014” gilead.com ↗
Filed	EU (EMA)	Emtriva	HIV infectious disease	2011-12-20	“Gilead’s marketing application for the Quad single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate was validated by EMA on December...” gilead.com ↗ “The Marketing Authorisation Application (MAA) for Emtriva was submitted for review under the centralized procedure in January 2003 by Triangle Pharmaceuticals.” gilead.com ↗ “Emtricitabine for the treatment of HIV were submitted to U.S. and European regulatory authorities in September and December of 2002, respectively” gilead.com ↗
Approved Indication not stated 3 milestones
Label expansions (2)	US (FDA)	EMTRIVA	—	2006-12-22 – 2008-05-16	fda.gov ↗
Approved	EU (EMA)	Emtriva	—	2003-10-24	europa.eu ↗
Approved	US (FDA)	EMTRIVA	—	2003-07-02	fda.gov ↗

Trials 269 · started per year

today

US approved 2003

EU approved 2003

199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 07 trials · 1 missed
Phase 0	NCT04898699	Nov 2021 → Jul 2022	HIV infectious disease	Columbia University	Completed	No outcome recorded
Phase 0	NCT04302896	Aug 2020 → Sep 2021	HIV infectious disease	Rhonda Brand	Completed	No outcome recorded
Phase 0	NCT03255915	Sep 2018 → Sep 2020	—	Oak Crest Institute of Science	Unknown	No outcome recorded
Phase 0	NCT03197961	Nov 2017 → Apr 2018	HIV infectious disease	Sharon Achilles	Completed	No outcome recorded
Phase 0	NCT03202511	Jun 2017 → Jul 2018	—	Indiana University	Completed	Missed primary
Phase 0	NCT02148094	Jan 2016 → Apr 2018	HIV infectious disease	University of Manitoba	Completed	No outcome recorded
Phase 0	NCT02431273	Jun 2015 → Dec 2016	—	Auritec Pharmaceuticals	Completed	No outcome recorded
Phase 126 trials · 1 missed
Phase 1	NCT07795307	Dec 2026 → Jul 2028 expected	Alzheimer disease	Brigham and Women's Hospital	Not yet recruiting	No outcome recorded
Phase 1	NCT07349758	Jan 2026 → Jan 2027 expected	—	Johns Hopkins University	Recruiting	No outcome recorded
Phase 1	NCT07210528	Jun 2025 → Mar 2026 overdue	Alzheimer disease	National University Hospital, Singapore	Recruiting	No outcome recorded
Phase 1	NCT06278389	Jan → Apr 2024	—	Jiangsu Aidea Pharmaceutical Group Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT04950530	Dec 2022 → Feb 2024	HIV infectious disease	Chelsea and Westminster NHS Foundation Trust	Completed	No outcome recorded
Phase 1	NCT05489406	Oct 2022 → Mar 2023	HIV infectious disease	Radboud University Medical Center	Completed	No outcome recorded
Phase 1	NCT03834909	Apr 2022 → Sep 2027	HIV infectious disease, pregnancy disorder	Johns Hopkins University	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT04853524	May → Jun 2021	—	Janssen Research & Development, LLC	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT04477096	Aug → Sep 2020	—	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04236453	Jan → Apr 2020	—	Janssen Pharmaceutica N.V., Belgium	Terminated	No outcome recorded
Phase 1	NCT03960645	Jun 2019 → Jul 2022	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 1	NCT03917420	Mar → Sep 2019	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT03836729	Feb → Mar 2019	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 1	NCT03270969	Jan → Sep 2018	—	University of Nebraska	Completed	No outcome recorded
Phase 1	NCT02985996	Feb → Nov 2017	HIV infectious disease	Emory University	Completed	No outcome recorded
Phase 1	NCT02984852	Dec 2016 → Feb 2017	—	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 1	NCT02904369	Oct 2016 → Nov 2017	HIV infectious disease	CONRAD	Completed	No outcome recorded
Phase 1	NCT02591420	Apr 2016 → Mar 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 1	NCT02475135	Jun → Aug 2015	—	Janssen Sciences Ireland UC	Completed	No outcome recorded
Phase 1	NCT01796431	Mar → Jul 2013	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 1	NCT01690403	Dec 2012 → Mar 2014	tuberculosis	Sanofi	Completed	No outcome recorded
Phase 1	NCT01276600	Jan → Oct 2011	HIV infectious disease	HIV Prevention Trials Network	Completed	No outcome recorded
Phase 1	NCT01108926	Jun → Oct 2010	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 1	NCT00660972	May 2008 → Jan 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00545558	Apr 2006 → Mar 2012	HIV infectious disease, hepatitis C virus infection	University of Cincinnati	Completed	No outcome recorded
Phase 1	NCT00002335	—	HIV infectious disease	Glaxo Wellcome	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT03304717	Dec 2025 → Dec 2029	Aicardi-Goutieres syndrome	Children's Hospital of Philadelphia	Withdrawn	No outcome recorded
Phase 1/2	NCT03652623	Jul 2018 → Nov 2023	HIV infectious disease	Hektoen Institute for Medical Research	Completed	No outcome recorded
Phase 1/2	NCT00971230	Oct 2009 → Jun 2010	HIV infectious disease	International AIDS Vaccine Initiative	Completed	No outcome recorded
Phase 1/2	NCT00016718	Aug 2001 → Jan 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 248 trials · 1 met primary · 6 missed
Phase 2	NCT06338826	Feb 2025 → Sep 2027 expected	HIV infectious disease	ANRS, Emerging Infectious Diseases	Not yet recruiting	No outcome recorded
Phase 2	NCT05993767	Dec 2024 → Jun 2025	HIV infectious disease	PENTA Foundation	Completed	No outcome recorded
Phase 2	NCT06511063	Oct 2024 → Nov 2026 expected	long COVID-19	Icahn School of Medicine at Mount Sinai	Recruiting	No outcome recorded
Phase 2	NCT06435026	Jun 2024 → Feb 2026	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT06101342	Dec 2023 → Jan 2028 expected	—	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2	NCT05957913	Jun 2023 → Jun 2027 expected	multiple sclerosis	Massachusetts General Hospital	Enrolling by invitation	No outcome recorded
Phase 2	NCT05052996	Oct 2021 → Dec 2023 overdue	HIV infectious disease	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2	NCT03954327	Mar 2021 → Oct 2022	primary biliary cholangitis	University of Alberta	Completed	No outcome recorded
Phase 2	NCT04066881	Dec 2020 → Dec 2024	HIV infectious disease	MRC/UVRI and LSHTM Uganda Research Unit	Completed	No outcome recorded
Phase 2	NCT04483674	Dec 2020 → Nov 2022	primary viral infectious disease	Anna Cruceta	Unknown	No outcome recorded
Phase 2	NCT03593655	Jan 2019 → Sep 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT03386578	Jul 2018 → Oct 2023	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02652260	Mar 2016 → Aug 2018	central nervous system disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT02556333	Sep 2015 → Aug 2016	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT02213328	Apr 2015 → Mar 2017	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02397694	Mar → Nov 2015	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT01769456	Mar 2013 → Nov 2015	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT01772823	Nov 2012 → Nov 2015	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT01605890	Jul 2012 → Dec 2015	—	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT01505114	Jun 2012 → Nov 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT01515813	Nov 2011 → Jul 2014	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Withdrawn	No outcome recorded
Phase 2	NCT01327651	Aug 2011 → Dec 2014	HIV infectious disease	HIV Prevention Trials Network	Completed	No outcome recorded
Phase 2	NCT01286740	Jan → Jul 2011	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT01140880	May 2010 → Mar 2013	substance abuse	Friends Research Institute, Inc.	Completed	No outcome recorded
Phase 2	NCT00949234	Mar → Jun 2010	HIV infectious disease	University of California, Los Angeles	Completed	No outcome recorded
Phase 2	NCT00958100	Aug 2009 → Nov 2010	AIDS	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 2	NCT01033942	Aug 2009 → Sep 2011	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	Missed primary
Phase 2	NCT00705679	Aug 2009 → Aug 2012	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00936715	Aug 2009 → Nov 2015	chronic hepatitis B virus infection	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00820118	May 2009 → May 2012	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT00827112	Mar 2009 → Jul 2010	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT00856323	Jan 2009 → Dec 2010	HIV infectious disease, substance-related disorder	Friends Research Institute, Inc.	Completed	No outcome recorded
Phase 2	NCT00474435	Nov 2008 → Dec 2009	HIV infectious disease, pulmonary tuberculosis	African Poverty Related Infection Oriented Research Initiative	Unknown	No outcome recorded
Phase 2	NCT00799136	Feb 2008 → Dec 2012	HIV infectious disease, lymphoma	Ontario Clinical Oncology Group (OCOG)	Completed	No outcome recorded
Phase 2	NCT00507507	Sep 2007 → Feb 2012	chronic hepatitis B virus infection	Gilead Sciences	Completed	Missed primary
Phase 2	NCT00507689	Sep 2007 → May 2011	chronic hepatitis B virus infection	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00524173	Aug 2007 → Feb 2017	hepatitis B virus infection	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Terminated	No outcome recorded
Phase 2	NCT00334256	Oct 2006 → Jul 2009	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 2	NCT00099632	Mar 2006 → Apr 2010	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00307489	Mar 2006 → Jan 2008	chronic hepatitis B virus infection	Gilead Sciences	Completed	Missed primary
Phase 2	NCT00743340	Nov 2005 → Feb 2017	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00204308	Mar 2005 → May 2007	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	Met primary
Phase 2	NCT00642291	Nov 2002 → Jul 2004	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00196599	Feb 1999 → Sep 2004	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT00017992	—	HIV infectious disease	Triangle Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT00102206	? → May 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00036452	? → Jan 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary
Phase 2	NCT00121017	—	HIV infectious disease, hepatitis C virus infection	Abbott	Withdrawn	No outcome recorded

Phase 2/313 trials · 1 met primary · 3 missed
Phase 2/3	NCT05140954	Apr → Dec 2023	HIV infectious disease	University of Washington	Completed	No outcome recorded
Phase 2/3	NCT04685512	Nov 2020 → Apr 2021	COVID-19	University Hospital, Caen	Completed	Missed primary
Phase 2/3	NCT04519125	Aug → Dec 2020	COVID-19	Hospital Universitario San Ignacio	Unknown	No outcome recorded
Phase 2/3	NCT02720094	Dec 2016 → May 2020	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 2/3	NCT02881320	Sep 2016 → Mar 2025 overdue	HIV infectious disease	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2/3	NCT02150993	Jan 2016 → May 2019	—	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2/3	NCT02285114	Jan 2015 → Nov 2019	—	Gilead Sciences	Completed	No outcome recorded
Phase 2/3	NCT02776748	Jan → May 2015	—	University of Washington	Completed	No outcome recorded
Phase 2/3	NCT02276612	Dec 2014 → Nov 2016	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2/3	NCT02016924	Jan 2014 → Jun 2025 overdue	AIDS	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2/3	NCT01854775	May 2013 → May 2020	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	Missed primary
Phase 2/3	NCT00039741	Aug 2002 → Aug 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary

Phase 350 trials · 15 met primary · 1 missed
Phase 3	NCT06630286	Oct 2024 → Apr 2026 overdue	HIV infectious disease	Gilead Sciences	Active not recruiting	Met primary
Phase 3	NCT05813964	Jun 2024 → Dec 2027 expected	HIV infectious disease	ANRS, Emerging Infectious Diseases	Recruiting	No outcome recorded
Phase 3	NCT06133686	Apr 2024 → Dec 2025 overdue	HIV infectious disease	MRC/UVRI and LSHTM Uganda Research Unit	Not yet recruiting	No outcome recorded
Phase 3	NCT06333808	Mar 2024 → Oct 2025 overdue	HIV infectious disease	Gilead Sciences	Active not recruiting	Met primary
Phase 3	NCT06250504	Feb 2024 → Apr 2026 overdue	HIV infectious disease	Africa Health Research Institute	Recruiting	No outcome recorded
Phase 3	NCT05630755	Feb 2023 → Oct 2024 overdue	HIV infectious disease	Merck Sharp & Dohme LLC	Active not recruiting	Met primary
Phase 3	NCT05457530	Aug 2022 → May 2023	HIV infectious disease, abdominal obesity-metabolic syndrome, obesity disorder	Prism Health North Texas	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT04994509	Aug 2021 → May 2024 overdue	—	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 3	NCT04925752	Jun 2021 → Aug 2024 overdue	—	Gilead Sciences	Active not recruiting	Met primary
Phase 3	NCT04416906	Oct 2020 → May 2023	HIV infectious disease	Judit Pich Martínez	Completed	No outcome recorded
Phase 3	NCT04140266	Sep 2020 → Nov 2021	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT04405271	Jul → Nov 2020	COVID-19	Hospital Italiano de Buenos Aires	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT04334928	Apr 2020 → Feb 2021	COVID-19	Plan Nacional sobre el Sida (PNS)	Completed	No outcome recorded
Phase 3	NCT04890626	Apr 2020 → Jul 2023	COVID-19	Instituto de Investigación Hospital Universitario La Paz	Completed	No outcome recorded
Phase 3	NCT04155554	Jan → Aug 2020	HIV infectious disease	University Hospital of Siena	Unknown	No outcome recorded
Phase 3	NCT03965923	Jan 2020 → May 2024	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT04051970	Nov 2019 → Jun 2022	HIV infectious disease	ANRS, Emerging Infectious Diseases	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03727152	May 2019 → Apr 2023	HIV infectious disease	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
Phase 3	NCT03048422	Jan 2018 → Oct 2020	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Mixed
Phase 3	NCT03327155	Nov 2017 → Apr 2019	—	Kirby Institute	Completed	No outcome recorded
Phase 3	NCT03164564	Nov 2017 → Nov 2020 overdue	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Active not recruiting	Met primary
Phase 3	NCT02842086	Sep 2016 → Jan 2019	—	Gilead Sciences	Terminated	Met primary
Phase 3	NCT02707601	Apr 2016 → Sep 2017	HIV infectious disease, hepatitis C virus infection	Gilead Sciences	Completed	Met primary
Phase 3	NCT02588820	Apr 2016 → Nov 2018	HIV infectious disease	David Garcia Cinca	Unknown	No outcome recorded
Phase 3	NCT02870790	Mar 2016 → Mar 2019	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 3	NCT02616029	Dec 2015 → Oct 2018	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02431247	Jul 2015 → Mar 2017	immunodeficiency disease	Janssen Sciences Ireland UC	Completed	Met primary
Phase 3	NCT02469246	Jun 2015 → Dec 2017	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 3	NCT02269917	Mar 2015 → Feb 2017	HIV infectious disease	Janssen R&D Ireland	Completed	Met primary
Phase 3	NCT02071082	Feb 2014 → Jan 2015	HIV infectious disease, hepatitis B virus infection	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01701882	Sep 2012 → Nov 2013	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 3	NCT01352715	Mar 2012 → Oct 2014	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Met primary
Phase 3	NCT01533259	Jan → Nov 2012	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01495702	Dec 2011 → Nov 2013	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01440569	Sep 2011 → Aug 2012	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01195467	Oct 2010 → Jun 2013	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 3	NCT00737568	Sep 2008 → Nov 2011	chronic hepatitis B virus infection	Gilead Sciences	Completed	Missed primary
Phase 3	NCT00495651	Mar 2008 → Jan 2015	HIV infectious disease, tuberculosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	Met primary
Phase 3	NCT00115609	Jan 2006 → Nov 2009	HIV infectious disease, tuberculosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 3	NCT00118898	Sep 2005 → Nov 2009	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 3	NCT00117676	Feb 2005 → Apr 2007	chronic hepatitis B virus infection	Gilead Sciences	Completed	Met primary
Phase 3	NCT00074581	Feb 2005 → May 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Met primary
Phase 3	NCT00323544	Oct 2004 → Jun 2007	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00221286	Sep 2004 → Jan 2007	HIV infectious disease, chronic hepatitis B virus infection	University Hospital, Bonn	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00158457	Jun 2004 → Dec 2006	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 3	NCT00112047	Jul 2003 → Feb 2005	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 3	NCT00196612	Apr 2001 → Sep 2004	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT00006208	Aug 2000 → ?	HIV infectious disease	Triangle Pharmaceuticals	Unknown	No outcome recorded
Phase 3	NCT00002362	Aug 1999 → ?	HIV infectious disease	Triangle Pharmaceuticals	Suspended	No outcome recorded
Phase 3	NCT00002416	—	HIV infectious disease	Triangle Pharmaceuticals	Completed	No outcome recorded

Phase 495 trials · 9 met primary · 7 missed
Phase 4	NCT07476339	Jun 2026 → Jun 2027 expected	HIV infectious disease	CAN Community Health	Recruiting	No outcome recorded
Phase 4	NCT07678268	Jul 2025 → Jul 2026 overdue	HIV infectious disease	Mexican Social Security Institute	Recruiting	No outcome recorded
Phase 4	NCT06337032	Aug 2024 → Mar 2034 expected	HIV infectious disease	Gilead Sciences	Recruiting	No outcome recorded
Phase 4	NCT06602622	Aug 2024 → Nov 2025 overdue	HIV wasting syndrome	Mexican Social Security Institute	Recruiting	No outcome recorded
Phase 4	NCT06375304	May 2024 → Jun 2026 overdue	HIV infectious disease	McGill University Health Centre/Research Institute of the McGill University Health Centre	Not yet recruiting	No outcome recorded
Phase 4	NCT06374758	Apr 2024 → May 2026 overdue	HIV infectious disease	University of Missouri-Columbia	Recruiting	No outcome recorded
Phase 4	NCT06104306	Dec 2023 → Jan 2025	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT05898841	May 2023 → Jul 2025	HIV infectious disease, metabolic dysfunction-associated steatotic liver disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT07006246	May 2023 → Nov 2025 overdue	HIV infectious disease	Professor Francois Venter	Active not recruiting	No outcome recorded
Phase 4	NCT04944654	Jan → May 2023	HIV infectious disease	Chelsea and Westminster NHS Foundation Trust	Terminated	No outcome recorded Stop: Business
Phase 4	NCT05663892	Nov 2022 → Nov 2024 overdue	HIV infectious disease	Maple Leaf Research	Active not recruiting	No outcome recorded
Phase 4	NCT05243602	Feb 2022 → Apr 2023	HIV infectious disease	University of Nairobi	Completed	No outcome recorded
Phase 4	NCT04388904	Sep 2021 → Apr 2024	HIV infectious disease	The Crofoot Research Center, Inc.	Completed	No outcome recorded
Phase 4	NCT05147740	Jul 2021 → Dec 2022	HIV infectious disease	Tulika Singh, MD	Unknown	No outcome recorded
Phase 4	NCT04666792	Mar 2021 → Dec 2024	HIV infectious disease	University of Washington	Completed	Met primary
Phase 4	NCT04183738	Feb 2021 → Dec 2022	Epstein-Barr virus infection, HIV infectious disease, cytomegalovirus infection, human herpesvirus 8 infection +1	Kirby Institute	Withdrawn	No outcome recorded
Phase 4	NCT04530630	Nov 2020 → Aug 2024	HIV infectious disease, transplant rejection	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT06177574	Oct 2020 → Oct 2023	HIV infectious disease	Carmen Hidalgo Tenorio	Completed	No outcome recorded
Phase 4	NCT04311957	Sep 2020 → May 2022	HIV infectious disease	Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic	Unknown	Met primary
Phase 4	NCT04295460	Mar 2020 → Jan 2022	HIV infectious disease	Hospitales Universitarios Virgen del Rocío	Unknown	Missed primary
Phase 4	NCT04298697	Feb 2020 → Aug 2022	HIV infectious disease	Emory University	Completed	No outcome recorded
Phase 4	NCT04054089	Jan 2020	HIV infectious disease	Cristina Mussini	Completed	Missed primary
Phase 4	NCT04538040	Dec 2019 → Nov 2021	HIV infectious disease	Quest Clinical Research	Completed	No outcome recorded
Phase 4	NCT03675815	Dec 2019 → Jan 2024	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT03858478	Nov 2019 → Mar 2021	—	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	Unknown	No outcome recorded
Phase 4	NCT04240509	Nov 2019 → Dec 2021	HIV infectious disease	The Miriam Hospital	Unknown	No outcome recorded
Phase 4	NCT03711253	Oct 2019 → Jun 2023	—	University of Southern California	Unknown	No outcome recorded
Phase 4	NCT04039217	Sep 2019 → Aug 2020	HIV infectious disease	Emory University	Completed	No outcome recorded
Phase 4	NCT03797014	Apr 2019 → Nov 2022	HIV infectious disease, hepatitis B virus infection	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT03771638	Feb 2019 → Apr 2020	—	Public Health Foundation Enterprises, Inc.	Completed	Missed primary
Phase 4	NCT03499483	Jan 2019 → Mar 2020	—	Fenway Community Health	Completed	No outcome recorded
Phase 4	NCT03348163	Jun 2018 → Dec 2020	HIV infectious disease	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02844634	May 2018 → May 2020	HIV infectious disease, syphilis	British Columbia Centre for Disease Control	Completed	No outcome recorded
Phase 4	NCT04225325	May 2018 → Sep 2019	HIV infectious disease	ADRIANO LAZZARIN, MD	Unknown	No outcome recorded
Phase 4	NCT03693508	Apr 2018 → May 2020	HIV infectious disease, immunodeficiency disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT03360682	Apr 2018 → May 2020	HIV infectious disease, disease related to solid organ transplantation	Fundacion Clinic per a la Recerca Biomédica	Completed	No outcome recorded
Phase 4	NCT04965662	Jan 2018 → Mar 2021	HIV infectious disease	Guy's and St Thomas' NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT03017872	Nov 2017 → Nov 2022	HIV infectious disease	Kirby Institute	Unknown	Met primary
Phase 4	NCT03350672	Nov 2017 → Mar 2018	HIV infectious disease	Philadelphia Fight	Completed	No outcome recorded
Phase 4	NCT03120936	Aug 2017 → Aug 2020	—	Public Health Foundation Enterprises, Inc.	Completed	No outcome recorded
Phase 4	NCT04050371	Aug 2017 → May 2018	—	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT03220152	Jul 2017 → Jul 2019	—	Oswaldo Cruz Foundation	Unknown	No outcome recorded
Phase 4	NCT02593409	May 2017 → Apr 2018	HIV infectious disease	MRC/UVRI and LSHTM Uganda Research Unit	Unknown	No outcome recorded
Phase 4	NCT03160105	May 2017 → Apr 2018	HIV infectious disease	Calmy Alexandra	Completed	No outcome recorded
Phase 4	NCT03163277	May 2017 → Jun 2020	HIV infectious disease, cognitive disorder	Giovanni Di Perri	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT03052010	Feb 2017 → Dec 2020	HIV infectious disease	University of Washington	Completed	Met primary
Phase 4	NCT03058835	Sep 2016 → Dec 2025	—	Rutgers, The State University of New Jersey	Unknown	No outcome recorded
Phase 4	NCT02771054	May 2016 → Jul 2018	HIV infectious disease	Göteborg University	Completed	No outcome recorded
Phase 4	NCT02584140	May 2016 → May 2019	—	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT02656511	Dec 2015 → May 2027 expected	HIV infectious disease	University of California, San Francisco	Active not recruiting	No outcome recorded
Phase 4	NCT03033836	Dec 2015 → Jun 2019	HIV infectious disease	Fundación Huésped	Completed	No outcome recorded
Phase 4	NCT02530060	Aug → Sep 2015	—	Janssen Pharmaceutical K.K.	Completed	No outcome recorded
Phase 4	NCT02042001	Jul 2015 → Jul 2017	HIV infectious disease, cognitive disorder, mixed anxiety and depressive disorder	Azienda Ospedaliera San Gerardo di Monza	Completed	No outcome recorded
Phase 4	NCT02198443	Jun 2015 → Jul 2016	HIV infectious disease	Fundacion Clinic per a la Recerca Biomédica	Completed	No outcome recorded
Phase 4	NCT02447016	May 2015 → Dec 2016	HIV infectious disease	Sheba Medical Center	Terminated	No outcome recorded
Phase 4	NCT02327702	Jan → Jul 2015	chronic hepatitis B virus infection, pregnancy disorder	Asian-Pacific Alliance of Liver Disease, Beijing	Unknown	No outcome recorded
Phase 4	NCT02327676	Jan → Jul 2015	chronic hepatitis B virus infection	Asian-Pacific Alliance of Liver Disease, Beijing	Unknown	No outcome recorded
Phase 4	NCT02327689	Jan → Jul 2015	chronic hepatitis B virus infection	Asian-Pacific Alliance of Liver Disease, Beijing	Unknown	No outcome recorded
Phase 4	NCT02327715	Jan → Jul 2015	chronic hepatitis B virus infection, pregnancy disorder	Asian-Pacific Alliance of Liver Disease, Beijing	Unknown	No outcome recorded
Phase 4	NCT02246998	Dec 2014 → Jan 2016	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT02327663	Dec 2014 → Jun 2017	chronic hepatitis B virus infection	Asian-Pacific Alliance of Liver Disease, Beijing	Unknown	No outcome recorded
Phase 4	NCT02206555	Nov 2014 → Nov 2016	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT02237027	Oct 2014 → Dec 2016	—	CHU de Quebec-Universite Laval	Completed	No outcome recorded
Phase 4	NCT02211690	Aug 2014 → Nov 2015	HIV infectious disease	Andrew Carr	Completed	No outcome recorded
Phase 4	NCT01855867	May 2013 → Apr 2014	HIV infectious disease	Kenneth H. Mayer, MD	Completed	No outcome recorded
Phase 4	NCT01367236	Jan 2013 → Oct 2015	HIV infectious disease, cognitive disorder	Imperial College London	Completed	Missed primary
Phase 4	NCT01715636	Dec 2012 → Jul 2014	—	Andrew Carr	Completed	No outcome recorded
Phase 4	NCT02775929	Nov 2012 → Jun 2016	HIV infectious disease	University of Washington	Completed	No outcome recorded
Phase 4	NCT02065986	Oct 2012 → Nov 2014	HIV infectious disease	Medical Research Council	Completed	No outcome recorded
Phase 4	NCT01602822	Feb → May 2012	HIV infectious disease	Kenneth H. Mayer, MD	Terminated	No outcome recorded
Phase 4	NCT01458977	Jan 2012 → Feb 2014	HIV infectious disease, hyperlipidemia	Fight AIDS and Infectious Diseases Foundation	Completed	Met primary
Phase 4	NCT01214759	May 2011 → Dec 2013	HIV infectious disease	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT01285050	Jan 2011 → Apr 2015	HIV infectious disease, hepatitis C virus infection	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT00955968	Jan 2010 → Aug 2016	HIV infectious disease	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	No outcome recorded
Phase 4	NCT01025427	Dec 2009 → Nov 2012	HIV infectious disease	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT00869960	Mar 2009 → Dec 2010	—	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT01772940	Dec 2008 → Oct 2011	HIV infectious disease	Centre Hospitalier Universitaire Saint Pierre	Completed	Missed primary
Phase 4	NCT00772902	Oct 2008 → Sep 2009	—	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00724711	Jul 2008 → Mar 2011	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 4	NCT00615745	Apr 2008 → Nov 2010	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00594646	Feb 2008 → Mar 2010	HIV infectious disease	Fenway Community Health	Completed	No outcome recorded
Phase 4	NCT00442962	May 2007 → Jul 2010	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 4	NCT00362687	Nov 2006 → May 2008	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00414635	Aug 2006 → Dec 2009	HIV infectious disease	Community Research Initiative of New England	Completed	No outcome recorded
Phase 4	NCT00365612	Jul 2006 → Oct 2007	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 4	NCT00324649	May 2006 → Mar 2008	—	Gilead Sciences	Completed	Met primary
Phase 4	NCT00389194	Apr 2006 → Oct 2008	HIV infectious disease	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00885664	Oct 2005 → Sep 2009	HIV infectious disease	University of Cincinnati	Completed	Missed primary
Phase 4	NCT00323492	Sep 2005 → Jul 2007	HIV infectious disease	Gilead Sciences	Completed	Met primary
Phase 4	NCT00084136	May 2005 → May 2010	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	Mixed
Phase 4	NCT00924898	Jan 2005 → Nov 2013	HIV infectious disease	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 4	NCT00106379	Oct 2004 → Jan 2007	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00127959	Mar 2004 → Aug 2006	HIV infectious disease, hepatitis B virus infection	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00344461	Mar 2004 → Jul 2008	HIV infectious disease	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT00055120	Mar 2003 → Sep 2006	AIDS-related disorder, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Missed primary

Phase not applicable26 trials · 1 missed
—	NCT07584122	Sep 2025 → Dec 2026 expected	HIV infectious disease	Oswaldo Cruz Foundation	Recruiting	No outcome recorded
—	NCT04778514	Dec 2022 → Sep 2023	HIV infectious disease	Population Council	Completed	No outcome recorded
—	NCT04593680	Jan 2022 → Oct 2023 overdue	—	Thai Red Cross AIDS Research Centre	Active not recruiting	No outcome recorded
—	NCT04274595	Feb 2020 → Nov 2021	psoriasis	Nîmes University Hospital	Completed	No outcome recorded
—	NCT03877536	Mar 2019 → Sep 2023	HIV infectious disease	Henry M. Jackson Foundation for the Advancement of Military Medicine	Withdrawn	No outcome recorded
—	NCT04583267	Aug 2018 → Dec 2022	HIV infectious disease	Yonsei University	Unknown	No outcome recorded
—	NCT03394196	Jul 2018 → May 2020	—	University of Washington	Terminated	No outcome recorded Stop: Business
—	NCT03459157	Nov 2017 → Dec 2020	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
—	NCT03113123	May 2017 → May 2024	HIV infectious disease	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
—	NCT03512964	Nov 2016 → Sep 2020	HIV infectious disease	Johns Hopkins University	Completed	No outcome recorded
—	NCT02495779	Jul 2015 → Nov 2017	HIV infectious disease	James Egan	Completed	No outcome recorded
—	NCT02449733	May 2015 → Oct 2016	HIV infectious disease	Emory University	Completed	No outcome recorded
—	NCT02043015	Feb 2015 → Oct 2016	HIV infectious disease	Emory University	Completed	No outcome recorded
—	NCT01571128	Nov 2014 → Mar 2016	HIV infectious disease	New York University	Completed	No outcome recorded
—	NCT01989611	Jun 2014 → Mar 2016	HIV infectious disease	Oswaldo Cruz Foundation	Unknown	No outcome recorded
—	NCT04318210	Oct 2012 → Jul 2014	HIV infectious disease	Centers for Disease Control and Prevention	Completed	No outcome recorded
—	NCT01632995	Oct 2012 → Feb 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT01583439	Sep 2012 → Feb 2013	HIV infectious disease	Harvard School of Public Health (HSPH)	Terminated	No outcome recorded Stop: Enrollment
—	NCT01509508	Mar 2012 → Jun 2016	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	Missed primary
—	NCT02097381	Apr 2010 → Mar 2014	HIV infectious disease	University of Roma La Sapienza	Unknown	No outcome recorded
—	NCT00357552	Jan 2008 → Oct 2010	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
—	NCT00525733	Oct 2007 → Dec 2013	HIV infectious disease	Rockefeller University	Completed	No outcome recorded
—	NCT00414518	Jan 2007 → Feb 2010	HIV infectious disease	University of Colorado, Denver	Completed	No outcome recorded
—	NCT00346567	Jun 2006 → Oct 2010	HIV infectious disease	Rigshospitalet, Denmark	Completed	No outcome recorded
—	NCT00152061	Jan → Aug 2005	HIV infectious disease	Stanford University	Completed	No outcome recorded
—	NCT00087464	—	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded Stop: Enrollment

Comparator or background therapy192 trials
Phase 1	NCT04500847 Comparator	Dec 2021 → Mar 2026 overdue	cognitive impairment with or without cerebellar ataxia, early-onset autosomal dominant Alzheimer disease	Butler Hospital	Recruiting	No outcome recorded
Phase 1	NCT04760691 Comparator	Mar 2021 → Mar 2025	HIV infectious disease	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT04424264 Background	Dec 2019 → Oct 2020	HIV infectious disease, tuberculosis	Professor Francois Venter	Completed	No outcome recorded
Phase 1	NCT03719053 Background	Oct 2018 → Jun 2020	—	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT03186482 Comparator	Jun 2017 → Jan 2018	HIV infectious disease	St. Stephens Clinical Research	Completed	No outcome recorded
Show all 192 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 120

Date	Issuer	Release
2026-07-29	GlaxoSmithKline	Results Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 gsk.com ↗ New real-world data from the US-based OPERA cohort showed CAB+RPV LA dosed every two months maintained virologic suppression comparable to daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in nearly 6,800 virologically suppressed adults living with HIV.
2026-07-29	ViiV Healthcare	Results CABENUVA DEMONSTRATES SUPERIORITY TO DAILY ORAL THERAPY IN ADOLESCENTS LIVING WITH HIV, AS ViiV HEALTHCARE HIGHLIGHTS NEW LONG-ACTING INJECTABLE DATA AT AIDS 2026 viivhealthcare.com ↗ New real-world data from the US-based OPERA cohort showed CAB+RPV LA dosed every two months maintained virologic suppression comparable to daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in nearly 6,800 virologically suppressed adults living with HIV.
2026-07-27	GlaxoSmithKline	Results ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV gsk.com ↗ Data show that Dovato (dolutegravir/lamivudine (DTG/3TC)) demonstrated non-inferior efficacy to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in treatment-naïve adults living with HIV, including people with high viral loads or a low CD4+ cell count1.
2026-06-11	Jiangsu Aidea Pharmaceutical Group Co., Ltd.	Results 再下一城！艾迪药业ACC017、艾诺米替首次亮相美国微生物学会年会 aidea.com.cn ↗ 进入联合治疗期后（联合FTC/TAF），至第29天，超过90%的参研者实现HIV-1 RNA < 50 copies/mL的病毒学抑制。
2026-05-25	Jiangsu Aidea Pharmaceutical Group Co., Ltd.	Results INTEREST 2026 \| 艾迪药业三项成果亮相非洲顶级HIV学术舞台 aidea.com.cn ↗ 进入联合治疗（联合FTC/TAF）至第29天，各组病毒载量降幅均为2.82-2.83 log10 copies/mL，且80%-90%的受试者HIV-1 RNA <50 copies/mL。
2025-11-19	Merck Sharp & Dohme LLC	Results Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection merck.com ↗ The success criterion for the primary efficacy hypothesis, as measured by the percentage of participants with HIV-1 RNA levels <50 copies/mL at Week 48, was met, with DOR/ISL demonstrating non-inferiority to once-daily oral bictegravir/emtricitabine/tenofovir alafenamide i [BIC/FTC/TAF (50 mg/200 mg/25 mg)].
2025-10-19	Gilead Sciences	Results Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025 gilead.com ↗ New Data Show Higher Treatment Satisfaction After Switching from IM CAB+RPV to Biktarvy ®
2025-10-15	Gilead Sciences	Results Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention gilead.com ↗ In the group of BICSTaR study participants with 5 years of real-world follow-up, Biktarvy continued to demonstrate sustained viral suppression, a favorable safety and tolerability profile, and a high barrier to resistance.
2025-04-17	Jiangsu Aidea Pharmaceutical Group Co., Ltd.	Results 民族创新之光！艾诺米替144周数据发布 aidea.com.cn ↗
2024-11-07	ViiV Healthcare	Results ViiV HEALTHCARE EXPANDS ON REAL-WORLD DATA SUPPORTING USE OF LONG-ACTING THERAPIES IN DIVERSE PATIENT POPULATIONS AT HIV GLASGOW viivhealthcare.com ↗ RUMBA’s week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF
2024-07-24	Gilead Sciences	Results Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024 gilead.com ↗ Lenacapavir also demonstrated superior prevention of HIV infections when compared with once-daily oral Truvada (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF).
2024-07-23	GlaxoSmithKline	Results ViiV Healthcare announces positive new data for Apretude use during pregnancy at AIDS 2024 gsk.com ↗ The findings showed that cabotegravir LA for PrEP was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period.
2024-07-23	GlaxoSmithKline	Results ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1 gsk.com ↗ Findings showed that switching to DTG/3TC in virologically suppressed adults living with HIV demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF.
2024-07-23	ViiV Healthcare	Results ViiV HEALTHCARE ANNOUNCES POSITIVE NEW DATA FOR APRETUDE USE DURING PREGNANCY AT AIDS 2024 viivhealthcare.com ↗ The findings showed that cabotegravir LA for PrEP was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period.
2023-09-19	GlaxoSmithKline	Regulatory European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention gsk.com ↗
2023-09-19	ViiV Healthcare	Regulatory EUROPEAN COMMISSION AUTHORISES ViiV HEALTHCARE’S APRETUDE (CABOTEGRAVIR LONG-ACTING AND TABLETS) FOR HIV PREVENTION viivhealthcare.com ↗ today announced that the European Commission has authorised Apretude (cabotegravir long-acting (LA) injectable and tablets) for HIV prevention.
2023-07-24	GlaxoSmithKline	Regulatory ViiV Healthcare’s cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency gsk.com ↗ GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, welcomed a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for cabotegravir long-acting (LA) injectable and tablets for HIV prevention.
2023-07-24	ViiV Healthcare	Regulatory ViiV HEALTHCARE’S CABOTEGRAVIR FOR HIV PREVENTION RECEIVES POSITIVE CHMP OPINION FROM EUROPEAN MEDICINES AGENCY viivhealthcare.com ↗
2023-07-23	Gilead Sciences	Results New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a broad range of people with HIV.
2023-02-23	GlaxoSmithKline	Results ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1 gsk.com ↗ 12-month findings from the SOLAR study showed that the every-two-month regimen of CAB+RPV LA demonstrated non-inferior efficacy compared to continuation of daily oral BIC/FTC/TAF
2023-02-23	ViiV Healthcare	Results ViiV HEALTHCARE ANNOUNCES POSITIVE DATA DEMONSTRATING LONG-ACTING INJECTABLE CABENUVA (CABOTEGRAVIR, RILPIVIRINE) IS AS EFFECTIVE AS DAILY ORAL BIKTARVY (BIC/FTC/TAF) FOR THE TREATMENT OF HIV-1 viivhealthcare.com ↗ Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV LA from BIC/FTC/TAF, and who completed a survey (n=425), preferred the long-acting regimen.
2022-10-28	GlaxoSmithKline	Regulatory European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention gsk.com ↗
2022-07-28	GlaxoSmithKline	Results ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets gsk.com ↗
2022-07-28	ViiV Healthcare	Results ViiV HEALTHCARE ANNOUNCES NEW DATA AT AIDS 2022 FROM UNBLINDED PHASE OF HPTN 084 STUDY IN WOMEN IN SUB SAHARAN AFRICA SHOWING CONTINUED SUPERIOR EFFICACY OF INJECTABLE CABOTEGRAVIR LONG-ACTING FOR PREP OVER DAILY, ORAL TDF/FTC TABLETS viivhealthcare.com ↗ No new HIV infections were observed in participants who initiated cabotegravir injections in the year following study unblinding
2021-12-21	ViiV Healthcare	Regulatory ViiV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE (CABOTEGRAVIR EXTENDED-RELEASE INJECTABLE SUSPENSION), THE FIRST AND ONLY LONG-ACTING INJECTABLE OPTION FOR HIV PREVENTION viivhealthcare.com ↗ today announced that the U.S. Food and Drug Administration (FDA) approved Apretude, the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually acquired HIV-1.
2021-12-20	GlaxoSmithKline	Regulatory ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention gsk.com ↗ The long-acting injectable was approved for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and who have a negative HIV-1 test prior to initiation.
2020-10-05	GlaxoSmithKline	Results ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1 gsk.com ↗ Dolutegravir plus lamivudine continues to demonstrate long-term non-inferior efficacy compared to dolutegravir plus TDF/FTC with benefits beyond viral suppression.
2020-07-08	Gilead Sciences	Results Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders gilead.com ↗ Baseline prevalence and longitudinal trends in HIV-associated sexual risk behaviors during the DISCOVER trial suggest that risk compensation, defined as an increase in risk behavior due to a reduction in perceived risk, did not occur among study participants.
2019-11-06	Gilead Sciences	Results Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials gilead.com ↗ Across all treatment groups no participants developed treatment failure with treatment-emergent resistance.
2019-11-06	Gilead Sciences	Results Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® gilead.com ↗ Descovy demonstrated non-inferior efficacy to Truvada through 96 weeks and statistically significant differences over Truvada for certain key measurements of bone and renal safety assessed in the study, which were pre-specified secondary endpoints.
2019-10-03	Gilead Sciences	Regulatory U.S. Food and Drug Administration Approves Descovy® for HIV Pre-Exposure Prophylaxis (PrEP) gilead.com ↗ Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration ( FDA ) approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF).
2019-07-24	GlaxoSmithKline	Results ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance gsk.com ↗ Both the GEMINI 1 & 2 studies showed that dolutegravir plus lamivudine continued to offer non-inferior efficacy to dolutegravir plus TDF/FTC at Week 96.
2019-07-23	Gilead Sciences	Results Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada® gilead.com ↗ At Week 4, levels of TFV-DP in PBMCs were 6.3-fold higher with Descovy compared with Truvada, resulting in 98 percent of participants receiving Descovy had drug levels above the EC90 compared with 68 percent of participants taking Truvada.
2019-07-22	Gilead Sciences	Results Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance gilead.com ↗ The studies further demonstrate the potential for Biktarvy to be an important treatment option for appropriate patients.
2019-04-11	Janssen Research & Development, LLC	Results Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks jnj.com ↗ A secondary endpoint of the study also showed that 97% of patients reported they were satisfied with their treatment.
2019-03-06	Gilead Sciences	Results Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women gilead.com ↗ Through Week 48, Biktarvy maintained high rates of virologic suppression with a low incidence of study drug-related adverse events and no treatment-emergent resistance.
2019-03-06	Gilead Sciences	Results Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance gilead.com ↗ The studies found high rates of virologic suppression with Biktarvy in treatment-experienced adults, regardless of pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
2019-03-06	Gilead Sciences	Results Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection gilead.com ↗ Descovy met the pre-established criteria for non-inferiority to Truvada using a stringent rate ratio statistical comparison, as demonstrated by the upper bound of the 95 percent confidence interval for HIV-1 infection rate ratio being less than the predefined non-inferiority margin of 1.62/100 PY.
2018-10-30	Gilead Sciences	Results Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of dolutegravir and emtricitabine/tenofovir alafenamide (50 mg) (DTG+FTC/TAF) through 96 weeks of therapy.
2018-10-03	Gilead Sciences	Results Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine (600/50/300mg, ABC /DTG/3TC) through 96 weeks of therapy.
2018-07-24	GlaxoSmithKline	Results ViiV Healthcare presents phase III data at AIDS 2018 from landmark GEMINI studies showing two-drug regimen of dolutegravir and lamivudine has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no emergence of resistance gsk.com ↗ The studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA <50c/mL, a standard measure of HIV control, at Week 48.
2018-07-24	Gilead Sciences	Results Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States gilead.com ↗
2018-06-25	Gilead Sciences	Regulatory European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the European Commission has granted Marketing Authorization for Biktarvy ® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.
2018-06-14	GlaxoSmithKline	Results ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients gsk.com ↗ The studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA <50 copies per millilitre (c/mL), a standard measure of HIV control, at Week 48.
2018-05-15	Gilead Sciences	Regulatory U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents gilead.com ↗ Truvada for PrEP is now indicated in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg.
2018-03-05	Gilead Sciences	Results Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine gilead.com ↗ Through Week 48, Biktarvy was found to be statistically non-inferior to ABC /DTG/3TC with a numerically lower incidence of mild or moderate study drug-related adverse events and no treatment-emergent resistance.
2018-03-05	Gilead Sciences	Results Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen gilead.com ↗ In the ongoing study, Biktarvy was found to be statistically non-inferior to regimens containing a bPI or boosted elvitegravir and demonstrated no treatment-emergent resistance at 48 weeks.
2017-10-25	Janssen Research & Development, LLC	Results Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial jnj.com ↗
2017-10-04	Gilead Sciences	Results Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens gilead.com ↗ In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks.
2017-08-10	Gilead Sciences	Regulatory Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ today announced that the U.S. Food and Drug Administration ( FDA ) has granted priority review for the company’s New Drug Application (NDA) for an investigational, fixed-dose combination
2017-07-25	Merck Sharp & Dohme LLC	Results Merck’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection merck.com ↗ In addition, through 48 weeks, statistically significantly fewer patients taking DOR/3TC/TDF reported pre-specified categories of neuropsychiatric events (dizziness, sleep disorders and disturbances, and inability to think clearly or concentrate) than patients receiving the EFV/FTC/TDF regimen.
2017-07-24	Gilead Sciences	Results Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗ In the ongoing studies, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing dolutegravir (50mg) (DTG) in combination with a dual-NRTI backbone.
2017-07-13	Gilead Sciences	Regulatory European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV gilead.com ↗
2017-06-12	Gilead Sciences	Regulatory Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment gilead.com ↗
2017-05-30	Gilead Sciences	Results Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies gilead.com ↗
2017-02-13	Gilead Sciences	Results Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV gilead.com ↗ Results found that the BIC+FTC/TAF and DTG+FTC/TAF regimens both demonstrated high virologic response rates at Week 24 and Week 48.
2016-10-24	Gilead Sciences	Results Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens gilead.com ↗ Results demonstrated regimens containing Descovy to be statistically non-inferior to regimens containing Truvada, with improvements in certain renal and bone laboratory parameters among patients receiving Descovy (FTC/TAF)-based regimens.
2016-09-12	Janssen Research & Development, LLC	Regulatory Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency jnj.com ↗
2016-07-21	Gilead Sciences	Results Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3b switch studies evaluating Odefsey ® (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for the treatment of HIV-1 infection met their primary objectives.
2016-07-18	GlaxoSmithKline	Results ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV gsk.com ↗ Results show statistically superior viral suppression (HIV-1 RNA <50 c/mL) rates at week 48: 82% versus 71% (adjusted difference 10.5%, 95% CI: 3.1%-17.8%, p=0.005) respectively.1
2016-04-25	Gilead Sciences	Regulatory European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for two doses of Descovy ® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection.
2016-04-04	Gilead Sciences	Regulatory U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy gilead.com ↗ Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV.
2016-03-01	Gilead Sciences	Regulatory U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Odefsey ® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.
2016-02-23	Gilead Sciences	Results Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens gilead.com ↗ At Week 48, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens, based on percentages of patients with HIV-1 RNA levels less than 50 copies/mL.
2016-02-01	Gilead Sciences	Regulatory European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV gilead.com ↗
2015-08-20	Gilead Sciences	Regulatory European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment gilead.com ↗ Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company’s Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA).
2015-07-21	Bristol-Myers Squibb	Results Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development bms.com ↗ The standard of care (SOC) control of atazanavir 300 mg and ritonavir 100 mg plus tenofovir disoproxyl fumarate 300 mg plus emtricitabine 200 mg in a fixed dose combination had a maximum median change in HIV-1 RNA of -2.39 log 10 c/mL from baseline through study discharge (Day 42).
2015-07-01	Gilead Sciences	Regulatory Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) gilead.com ↗
2015-04-07	Gilead Sciences	Regulatory Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment gilead.com ↗ Today’s filing is Gilead’s second F/TAF-based NDA submitted to the FDA for review.
2014-11-03	Merck Sharp & Dohme LLC	Results Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients merck.com ↗ The results showed a significantly lower incidence of one or more of reported CNS AEs (all causality) among the doravirine-treated group compared to the efavirenz-treated group (22.2 % vs. 43.5 %, respectively; p<0.001).
2014-07-22	Pfizer	Results ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1 pfizer.com ↗ The proportion of study participants who were virologically suppressed (HIV-1 RNA <50 copies/mL) at week 48 was 77.3% for MVC+DRV/r compared to 86.8% for FTC /TDF +DRV/r (95% confidence interval -15.0% to -4.4%).
2014-07-22	GlaxoSmithKline	Results ViiV Healthcare presents phase III data gsk.com ↗ The proportion of study participants who were virologically suppressed (HIV-1 RNA <50 copies/mL) at week 48 was 77.3% for MVC+DRV/r compared to 86.8% for FTC /TDF +DRV/r (95% confidence interval -15.0% to -4.4%).
2013-12-13	Gilead Sciences	Regulatory U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the single tablet HIV-1 regimen Complera ® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA
2013-10-16	Gilead Sciences	Results Gilead’s Single Tablet HIV Regimen Stribild® Demonstrates Durable Viral Suppression Through Three Years of Therapy gilead.com ↗ In these large-scale clinical trials, Stribild demonstrated high and durable viral suppression and a favorable safety profile over three years of therapy.
2013-05-28	Gilead Sciences	Regulatory European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection gilead.com ↗ This approval allows for the marketing of Stribild in all 27 countries of the European Union .
2012-11-15	Gilead Sciences	Results Gilead’s Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients gilead.com ↗
2012-11-15	Gilead Sciences	Results Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naïve HIV Patients gilead.com ↗ Complera demonstrated a statistically significant difference in efficacy compared to Atripla among patients with low baseline viral load (≤ 100,000 copies/mL), and was non-inferior to Atripla among patients with high baseline viral load (> 100,000 copies/mL).
2012-07-24	Gilead Sciences	Results Gilead’s Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens gilead.com ↗ The study met its 24-week primary endpoint, which found that switching to Complera was non-inferior to remaining on a ritonavir-boosted protease inhibitor regimen.
2012-05-11	Gilead Sciences	Regulatory FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration ( FDA ) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.
2012-03-08	Gilead Sciences	Results Data Show Gilead’s Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study gilead.com ↗ The study found that the Quad was non-inferior to a protease-based regimen of ritonavir-boosted atazanavir (ATV/r) plus Truvada ® (emtricitabine/tenofovir disoproxil fumarate) at 48 weeks of therapy among HIV-1 infected treatment-naïve adults.
2011-12-20	Gilead Sciences	Regulatory Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Marketing Authorisation Application (MAA) for the Quad single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults, submitted on November 24, 2011 , has been validated by the European Medicines Agency (EMA).
2011-12-05	Gilead Sciences	Results Gilead’s Boosting Agent, Cobicistat, Meets 48-Week Primary Objective in Pivotal Phase 3 Study gilead.com ↗ Discontinuation rates due to adverse events were 7.3 percent and 7.2 percent in the cobicistat and ritonavir arms of the study, respectively.
2011-11-28	Gilead Sciences	Regulatory Gilead Receives European Marketing Authorization for Eviplera(R), a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naive Adults gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for Eviplera ® (emtricitabine/rilpivirine/tenofovir disoproxil), a complete once-daily single-tablet regimen for the treatment of HIV-1 infection in antiretroviral treatment-naïve adults with a viral load less than or equal to 100,000 HIV-1 RNA copies/mL.
2011-10-27	Gilead Sciences	Regulatory Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet "Quad" HIV Regimen gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the "Quad", a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
2011-09-23	Gilead Sciences	Regulatory European CHMP Adopts Positive Opinion for Eviplera(R), a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection gilead.com ↗ The CHMP's positive recommendation will be reviewed by the European Commission, which has the authority to approve medicinal products for use in the 27 countries of the European Union (EU).
2011-08-15	Gilead Sciences	Results Gilead's Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective in Pivotal Phase 3 Clinical Study 102 gilead.com ↗ The primary endpoint analysis indicated that 88 percent of patients in the Quad arm compared to 84 percent in the Atripla (95% CI for the difference: -1.6% to 8.8%) achieved HIV RNA (viral load) of less than 50 copies/mL through week 48.
2011-08-10	Gilead Sciences	Regulatory U.S. Food and Drug Administration Approves Gilead Sciences' Complera(TM), a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults gilead.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has approved Complera(TM) (emtricitabine/rilpivirine/tenofovir disoproxil fumarate), a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.
2011-02-10	Gilead Sciences	Regulatory Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada(R) and TMC278 gilead.com ↗ Specifically, the FDA requested additional information on the analytical methodology and qualification data used to establish acceptable levels of recently identified degradants related to emtricitabine; this information has been included in the refiling.
2011-01-25	Gilead Sciences	Regulatory Gilead Sciences Receives Refuse to File Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada(R) and TMC278 gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has received a "refuse to file" notification from the U.S. Food and Drug Administration (FDA) regarding Gilead's New Drug Application (NDA) for the single-tablet regimen of Truvada (R) (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
2010-11-23	Gilead Sciences	Regulatory Gilead Sciences Submits New Drug Application to U.S. FDA for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for HIV gilead.com ↗
2010-09-13	Gilead Sciences	Results Gilead's Single-Tablet "Quad" HIV Regimen Maintains High Viral Suppression Through 48 Weeks in Phase II Study gilead.com ↗ At week 48, the proportion of patients who achieved HIV RNA (viral load) less than 50 copies/mL was 90 percent in the Quad arm and 83 percent in the Atripla arm (using an analysis where missing equals failure).
2010-09-03	Gilead Sciences	Regulatory Gilead Sciences Submits European Marketing Application for Once-Daily Single-Tablet Regimen of Truvada(R) and TMC278 for the Treatment of HIV Infection gilead.com ↗
2010-04-27	Gilead Sciences	Results Gilead Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals' TMC278 gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) announced today it has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg).
2010-01-06	Gilead Sciences	Results Phase II Clinical Trial of Gilead's Investigational Integrase-Based, Once-Daily, Fixed-Dose "Quad" Regimen Meets 24-Week Primary Objective gilead.com ↗ GS 9350-boosted atazanavir and Truvada had similar efficacy to ritonavir-boosted atazanavir and Truvada.
2008-10-26	Bristol-Myers Squibb	Results 96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir In Previously Untreated HIV-1 Infected Adult Patients bms.com ↗ The CASTLE results demonstrated the non-inferiority of REYATAZ/r once daily versus lopinavir/r twice daily, each as part of HIV combination therapy in previously untreated HIV-1 infected adult patients.
2007-12-17	Gilead Sciences	Regulatory European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection gilead.com ↗
2007-10-29	Gilead Sciences	Results Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients gilead.com ↗ Patients in both study arms maintained virological suppression at 48 weeks.
2007-07-23	Gilead Sciences	Results 144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney gilead.com ↗ today announced the presentation of 144-week data from an ongoing clinical trial, Study 934, comparing a once-daily regimen of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Sustiva(R) (efavirenz)
2006-12-15	Gilead Sciences	Results 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of 96-week data from an ongoing clinical trial, Study 934, in the Journal of Acquired Immune Deficiency Syndrome (JAIDS).
2006-10-09	Gilead Sciences	Regulatory Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) to European Medicines Agency gilead.com ↗ The MAA for ATRIPLA in the European Union was filed jointly by the three companies through a newly established three-way joint venture based in Ireland, Bristol-Myers Squibb Gilead Sciences And Merck Sharp & Dohme Limited.
2006-07-12	Gilead Sciences	Regulatory U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection gilead.com ↗ Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced the U.S. Food and Drug Administration (FDA) has granted approval of ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV-1 infection in adults.
2006-04-27	Gilead Sciences	Regulatory Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment gilead.com ↗
2006-03-08	Gilead Sciences	Regulatory U.S. FDA Grants Traditional Approval for Gilead's Once-Daily HIV Medications Truvada(R) and Viread(R); 48-Week Data from Pivotal Study 934 Added to U.S. Prescribing Information for Both Products gilead.com ↗ Traditional approval status was granted following FDA review of 48-week data from Study 934, the second confirmatory pivotal study for Viread.
2006-01-18	Gilead Sciences	Results Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com ↗ Publication Describes Superior Viral Suppression with Fewer Adverse Events Leading to Discontinuation for Patients Taking Viread and Emtriva at 48 Weeks
2006-01-09	Gilead Sciences	Results Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) gilead.com ↗
2005-11-17	Gilead Sciences	Results Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference gilead.com ↗ Hemoglobin levels also increased significantly from baseline.
2005-08-09	Gilead Sciences	Results Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) and Sustiva(R) (Efavirenz) gilead.com ↗ bioequivalence results from its second formulation of the fixed-dose combination of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Bristol-Myers Squibb's Sustiva(R) (efavirenz) for the treatment of HIV did not demonstrate bioequivalence to the individual products dosed separately.
2005-04-26	Gilead Sciences	Results Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada -emtricitabine and tenofovir disoproxil fumarate- and Sustiva -efavirenz- gilead.com ↗ Preliminary results from the bioequivalence study of the first formulation indicate that efavirenz levels in the blood are lower than those achieved with the recommended 600 mg dose of Sustiva alone and do not meet the definition of bioequivalence.
2005-02-03	Gilead Sciences	Results Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV gilead.com ↗ Gilead Sciences (Nasdaq:GILD) today announced preliminary 48-week data from the company's Study 934.
2004-10-31	Gilead Sciences	Results Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC gilead.com ↗ Although both triple-drug regimens are relatively convenient, we observed a difference in the two arms, with more patients discontinuing in the Combivir group due to adverse events.
2004-08-26	Gilead Sciences	Results Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV gilead.com ↗ Preliminary results show a statistically significant difference favoring Viread/Emtriva in the percentage of patients who achieved and maintained HIV RNA less than 400 copies/mL at 24 weeks, based on the FDA Time to Loss of Virologic Response algorithm (TLOVR).
2004-07-11	Gilead Sciences	Results Pivotal Studies of Gilead's Viread and Emtriva Published in Special International Aids Conference Issue of Journal of the American Medical Association gilead.com ↗ Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of results from two separate studies evaluating the efficacy and safety of Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) (emtricitabine), respectively, compared with stavudine (d4T), in combination with other antiretroviral agents.
2004-03-15	Gilead Sciences	Regulatory Gilead Submits Applications to U.S. and European Regulatory Authorities for Fixed Dose Co-Formulation of Viread and Emtriva gilead.com ↗ The company also announced the submission of its Marketing Authorisation Application (MAA) for the fixed dose co-formulation to the European Agency for the Evaluation of Medicinal Products (EMEA).
2003-11-25	Gilead Sciences	Results Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B gilead.com ↗ Gilead Sciences, Inc. (Nasdaq: GILD) today announced preliminary results from a Phase III clinical trial (Study FTCB-301) comparing the efficacy and safety of emtricitabine 200 mg once daily versus placebo in patients with chronic hepatitis B.
2003-10-28	Gilead Sciences	Regulatory Gilead Sciences' HIV Drug Emtriva Approved for Marketing in European Union gilead.com ↗ today announced that the European Commission has granted Marketing Authorisation for Emtriva(TM) (emtricitabine, 200 mg hard capsules and 10 mg/mL oral solution) in all 15 member states of the European Union.
2003-10-28	Gilead Sciences	Regulatory Gilead Sciences Announces Third Quarter 2003 Financial Results gilead.com ↗ Today, Gilead announced that the European Commission followed the recommendation of the CPMP and has granted Marketing Authorisation for the product.
2003-07-24	Gilead Sciences	Regulatory European CPMP Gives Positive Opinion on Emtriva, Gilead's New Once-Daily Treatment for HIV gilead.com ↗ The CPMP's positive opinion for Emtriva is the second that Gilead has received from the Committee for a new HIV treatment.
2003-07-14	Gilead Sciences	Results Phase III Trial of Emtriva, New Once-Daily Capsule for HIV, Shows Continued Response Through 60 Weeks gilead.com ↗ This study suggests that over time Emtriva continues to outperform stavudine, a thymidine-analogue NRTI, in terms of both its efficacy and tolerability,
2003-07-02	Gilead Sciences	Regulatory U.S. FDA Approves Gilead Sciences' Emtriva, a One-Capsule, Once-Daily Medication for the Treatment of HIV gilead.com ↗ Gilead Sciences (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing Emtriva(TM) (emtricitabine), a new 200 mg one-capsule, once-daily nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults in combination with other antiretroviral medications.
2003-02-11	Gilead Sciences	Results Phase III Data Show Emtricitabine Maintains Viral Load Suppression as Part of Once-Daily, Protease-Sparing Anti-HIV Regimen gilead.com ↗ At 48 weeks, 94 percent of patients receiving the once-daily regimen of emtricitabine, didanosine and efavirenz had HIV RNA levels (viral load) less than 400 copies/mL, compared to 92 percent randomized to continue therapy in the PI-based arm (intent to treat population, assays performed at local laboratories at investigational centers).

All press releases naming this drug 149 releases

Date	Issuer	Release
Show all 149 releases opens the full record — a long page

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 490 sources stand behind the page.

Field	Value	Cited text
Known as	emtricitabine	“The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing...” NCT06630286 ↗ 458 “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗ “This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide...” NCT02707601 ↗ “This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of...” NCT01632995 ↗ “This single-arm, single-site, open-label trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part...” NCT02556333 ↗ “The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance...” PMID 33315694 ↗ Apr 2021 “Participants on any stable second-generation integrase strand transfer inhibitor-based 3DR regimen with HIV-1 RNA < 50 copies/mL plasma for at least 3 months were randomized to...” PMID 39226296 ↗ Feb 2025 “The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how...” NCT04039217 ↗ “A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among...” NCT02042001 ↗ “The study seeks to assess the safety of and define blood and tissue benchmark concentrations of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in...” NCT05140954 ↗ Show 448 more sources
Known as	524-W-91	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	BW-524W91	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Coviracil	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	emtricitabina	“Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.” NCT03577782 ↗ 1 NCT02547844 ↗
Known as	emtricitabine (FTC)	“emtricitabine (FTC)” NCT01338025 ↗
Known as	Emtricitabine component of atripla	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of biktarvy	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of complera	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of descovy	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of eviplera	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of genvoya	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of odefsey	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of stribild	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of symtuza	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabine component of truvada	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtricitabinum	ChEMBL registry synonym — accepted as the source's own label CHEMBL885 ↗
Known as	Emtriva	“Emtriva (emtricitabine)” NCT00106379 ↗ 1 NCT04500847 ↗
Known as	Emtriva (Brand for emtricitabine)	“Emtriva (Brand for emtricitabine)” NCT03304717 ↗
Known as	FTC	“DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗ 173 “This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of...” NCT01632995 ↗ “This single-arm, single-site, open-label trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part...” NCT02556333 ↗ “Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T),...” NCT02016924 ↗ “The study seeks to understand how anti-HIV drug Biktarvy, which contains the drugs tenofovir alafenamide (TAF), emtricitabine (FTC), and bictegravir (BIC) is absorbed and how...” NCT04039217 ↗ “To conduct a phase 1b trial to determine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple ascending doses of emtricitabine (FTC) and...” NCT07795307 ↗ “This study aims: (1) to determine the optimal dose of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for daily oral pre-exposure prophylaxis (PrEP) during pregnancy...” NCT06435026 ↗ “In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/VESTED study, pregnant women were randomized to initiate dolutegravir (DTG) +...” PMID 38877762 ↗ Nov 2024 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir...” NCT02097381 ↗ Show 163 more sources
Action	Inhibit	“existing dual nucleoside analogue reverse transcriptase inhibitor therapy to coformulated tenofovir-emtricitabine or abacavir-lamivudine” PMID 24722774 ↗ Apr 2014
Modality	Other / unclassified	“the NRTIs ddI and FTC” NCT00016718 ↗
Route	Oral	“Will be administered as one 200-mg capsule orally daily” NCT00051831 ↗